Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis

Journal of Infectious Diseases

Volumn 180, Issue 5, 1999, Pages 1526-1535

  Fleuridor, R ^a   Lyles, R H ^b   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CD4 ANTIGEN; GLUCURONOXYLOMANNAN; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL MENINGITIS; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; QUANTITATIVE DIAGNOSIS;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, FUNGAL; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CRYPTOCOCCUS NEOFORMANS; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN ISOTYPES; MALE; MENINGITIS, CRYPTOCOCCAL; POLYSACCHARIDES;

EID: 0032701096     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315102     Document Type: Article

References (53)

1. 1. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515-548.
2. 2. Pirofski L, Casadevall A. Cryptococcus neoformans: paradigm for the role of antibody in immunity. Zentralbl Bakteriol 1996;284:475-495.
3. 3. Mukherjee J, Scharff MD, Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 1992; 60:4534-4541.
4. 4. Mukherjee J, Kozel TR, Casadevall A. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies. J Immunol 1998; 161: 3557-67.
5. 5. Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P. Protection of mice against experimental cryptococcosis by an anti-Cryptococcus neoformans monoclonal antibody. Infect Immun 1987; 55:749-52.
6. 6. Fleuridor R, Zhong Z, Pirofski L. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J Infect Dis 1998; 178: 1213-16.
7. 7. Moore RD, Chaisson RE. Natural history of opportunistic disease in HIV-infected urban clinical cohort. Ann Intern Med 1996; 124:633-42.
8. 8. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994; 19:1029-33.
9. 4. Hajjeh RA, Conn LA, Stephens DS, et al. Population-based multivariate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis 1999; 179:449-54.
10. 10. Houpt DC, Pfrommer GS, Young BJ, Larson TA, Kozel TR. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun 1994; 62:2857-64.
11. 11. Chen L, Goldman DL, Doering TL, Pirofski L, Casadevall A. The antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect Immun 1999;67:2218-24.
12. 12. DeShaw M, Pirofski L. Antibodies to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan are ubiquitous in the serum of HIV+ and HIV-individuals. Clin Exp Immunol 1995;99:425-32.
13. 13. Dromer F, Aucouturier P, Clauvel J-P, Saimot G, Yeni P. Cryptococcus neoformans antibody levels in patients with AIDS. Scan J Infect Dis 1988; 20:283-85.
14. 14. Abadi J, Pirofski L. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without HIV infection. J Infect Dis 1999;180:(in press).
15. 15. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med 1974;80:176-81.
16. 16. Kaplan MH, Rosen PP, Armstrong D. Cryptococcosis in a cancer hospital. Cancer 1977;39:2265-74.
17. 17. Tabone MD, Leverger G, Landman J, Aznar C, Boccon-Gibon L, Lasfargues G. Disseminated lymphonodular cryptococcosis in a child with X-linked hyper-IgM immunodeficiency. Pediatr Infect Dis J 1994;13:77-9.
18. 18. Iseki M, Anzo M, Yamashita N, Matsuo N. Hyper-IgM immunodeficiency with disseminated cryptococcosis. Acta Paediatr 1994;83:780-2.
19. 19. Smith JH, Nichols MM, Goldman AS, Schmalsteig FC, Goldblum RM. Disseminated cryptococcosis in an infant with severe combined immunodeficiency. Hum Pathol 1982; 13:500-3.
20. 20. Lewis JL, Rabinovich S. The wide spectrum of cryptococcal infections. Am J Med 1972; 53:315-22.
21. 21. Zhang H, Zhong Z, Pirofski L. Peptide epitopes recognized by a human anticryptococcal glucuronoxylomannan antibody. Infect Immun 1997;65: 1158-1164.
22. 22. Mukherjee J, Nussbaum G, Scharff MD, Casadevall A. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med 1995; 181:405-9.
23. 23. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994;38:1695-1702.
24. 24. Kaslow RA, Ostrow DG, Detels R, Phair J, Polk B, Rinaldo C. The Multicenter AIDS Cohort Study: rationale, organization and selected characterization of the participants. Am J Epidemiol 1987; 126:310-18.
25. 25. Goldman DL, Fries BC, Franzot SP, Montella L, Casadevall A. Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci USA 1998;95:14967-72.
26. 26. Cherniak R, Morris LC, Belay T, Spitzer ED, Casadevall A. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun 1995 ;63:1899-1905.
27. 27. Cherniak R, Morris LC, Anderson BC, Meyer SA. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans. Infect Immun 1991; 59:59-64.
28. 28. Abadi J, Kriedman J, Jefferis R, Mageed RA, Pirofski L. Human antibodies elicited by a pneumococcal vaccine express idiotypic determinants indicative of VH3 gene segment usage. J Infect Dis 1998; 178:707-16.
29. 29: Mageed RA, Moyes SP, Thompson KM, Natvig JB. Molecular and cellular aspects of human rheumatoid factor production and idiotypes. In: Shoenfeld Y, Kennedy RC, Ferrone S, eds. Idiotypes in Medicine: Autoimmunity. Infection and Cancer. Amsterdam: Elsevier, 1997:135-155.
30. 30. Pirofski L, Lui R, DeShaw M, Kressel AB, Zhong Z. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect Immun 1995;63:3005-14.
31. 31: Single-stranded, Filamentious Bacteriophage Vectors. In: Sambrook J, Fritsch, E.F., Maniatis T, eds. Molecular Cloning: A laboratory Manual. 2nd ed ed. New York: Cold Spring Harbor Laboratory Press, 1989: 4.21-4.32
32. 32. Littell RC, Milliken GA, Stroup WW, Wollinger RD, SAS system for mixed models. Cary, NC: SAS Institute, 1996.
33. 33. Conover WJ. A practical nonparametric statistics. New York, NY: John Wiley, 1980:229-39
34. 34. Aberg JA, Powderly WG. Cryptococcocal Disease: Implications of Recent Clinical Trials on Treatment and Management, In: Volberding PA, Jacobson MA, eds. AIDS Clinical Review 1997/1998. New York, New York: Marcel Dekker, 1998;229-48.
35. 35. Lucas AH, Granoff DM, Mandrell RE, Connolly CC, Shah AS, Powers DC. Oligoclonality of serum immunoglobulin G antibody responses to Streptococcus pneumoniae capsular polysaccharide serotypes 6B, 14, and 23F. Infect Immun 1997;65:5103-9.
36. 36. Lane CH, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B cell activation and immunoregulation in patients with AIDS. M Engl J Med 1983;309:453-8.
37. 37. Casadevall A, Perfect JR. Specific Immunity and Cytokines. In: Cryptococcus neoformans. First edition Ed. Washington, D.C.: American Society of Microbiology, 1998:223-71.
38. 38. Robbins JB, Schneerson R, Glode MP, et al. Cross-reactive antigens and immunity to diseases caused by encapsulated bacteria. J Allergy Clin Immunol 1975; 56:141-51.
39. 39. Yuan R, Casadevall A, Scharff MD. T cells cooperate with passive antibody to modify the course of Cryptococcus neoformans in mice. Proc Natl Acad Sci USA 1997;94:2483-88.
40. 40. Lyamuya EF, Maselle SY, Matre R. Serum immunoglobulin levels in asymptomatic HIV-1 seropositive adults and in patients with AIDS in Dar es Salaam, Tanzania. East Afr Med J 1994;71:24-8.
41. 41. White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992; 165:960-3.
42. 42. Perfect JR, Durack TD, Gallis HA. Cryptococcemia. Medicine 1983; 62: 98-109.
43. 43. Pirofski L, Casadevall A. The use of licensed vaccines for active immunization of the immunocompromised host. Clin Microb Rev 1998; 11:1-26.
44. 44. Kyong CU, Virella G, Fudenberg HH, Darby CP. X-linked immunodeficiency with increased IgM: clinical, ethic, and immunologic heterogeneity. Pediatr Res 1978; 12:1024-26.
45. 45. Marquis G, Montplaisir S, Pelletier M, Mousseau S, Auger P. Genetic resistance to murine cryptococcosis: Increased susceptibility in the CBA/N XID mutant strain of mice. Infect Immun 1985; 47:282-7.
46. 46. Berberian L, Goodglick L, Kipps TJ, Braun J. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 1993;261:1588-91.
47. 47. Karray S, Juompan L, Maroun RC, Isenberg G, Silverman GJ, Zouali M. Structural basis of the gp 120 superantigen-binding site on human immunoglobulins. J Immunol 1998; 161:6681-88.
48. 48. Bessudo A, Rassenti L, Havlir D, Richman D, Feigal E, Kipps TJ. Aberrant and unstable expression of immunoglobulin genes in persons infected with human immunodeficiency virus. Blood 1998;92:1317-23.
49. 49. Zhong Z, Pirofski L. Antifungal activity of a human antiglucuronoxylomannan antibody. Clin Diag Lab Immunol 1998;5:58-64.
50. 50. Sasso EH, Silverman GJ, Mannik M. Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup. J Immunol 1991;147:1877-83.
51. 51. Townsley-Fuchs J, Kam L, Fairhurst R, et al. Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission. J Clin Invest 1996; 98: 1794-1801.
52. 52. Russell MW, Sibley DA, Nikolova EB, Tomana M, Mesteeky J. IgA antibody as a non-inflammatory regulator of immunity, Biochem Soc Trans 1997;25: 466-70.
53. 53. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;325:73-80.